Robert Dreicer, MD from the Taussig Cancer Institute, explains that the survival benefits observed for abiraterone acetate (Zytiga) and sipuleucel-T (Provenge) are both in the range of 4 months. Additionally, post docetaxel the agent cabazitaxel also improves survival. Since all of these agents improve survival the questions becomes how do you use them, should you combine, and in which population.

OncLive TV

® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers. 

Prostate Cancer

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Robert Dreicer, MD, from the Taussig Cancer Institute, Discusses How New Treatments Have Improved Survival

Dr. Dreicer on Newer Prostate Therapy Survival Benefits